AERI · Aerie Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $194.13M | $83.14M | $69.89M | $0 | - | - |
| Cost of Revenue | $26.85M | $25.33M | - | $0 | - | - |
| Gross Profit | $167.29M | $57.80M | - | $0 | - | - |
| R&D | $75.84M | $74.01M | $91.38M | $86.12M | $72.08M | $52.39M |
| SG&A | $137.81M | $137.18M | $138.40M | $120.61M | $44.48M | $44.48M |
| Total Operating Expenses | $240.49M | $238.83M | $257.38M | $96.87M | $96.87M | - |
| D&A | $6.40M | $6.37M | $5.14M | $2.44M | $1.41M | $970.0K |
| Operating Income | ($46.35M) | ($155.69M) | ($187.49M) | ($209.74M) | ($145.69M) | ($96.87M) |
| Interest Expense | $28.90M | $26.50M | $2.50M | - | - | $2.54M |
| Income Tax | $593.0K | $5.25M | ($90.0K) | $3.0K | ($1.76M) | $193.0K |
| Net Income | ($74.81M) | ($183.10M) | ($199.58M) | ($232.57M) | ($145.10M) | ($99.06M) |
| EPS - Basic | ($3.99) | - | - | - | - | - |
| EPS - Diluted | ($3.99) | - | - | - | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $37.19M | $151.57M | $143.94M | $202.82M | $197.57M | $197.94M |
| Accounts Receivable | $68.83M | $56.02M | $38.35M | $2.71M | - | - |
| Inventory | $40.41M | $27.06M | $21.05M | $10.11M | - | - |
| Accounts Payable | $8.29M | $8.83M | $12.77M | $12.40M | $6.25M | $5.61M |
| Current Assets | $355.65M | $331.75M | $376.34M | $220.18M | $254.14M | $237.69M |
| Total Assets | $431.39M | $402.05M | $452.61M | $285.04M | $290.28M | $248.25M |
| Current Liabilities | $124.99M | $104.47M | $83.65M | $50.78M | $25.18M | $19.37M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $448.72M | $378.08M | $285.66M | $57.24M | $154.68M | $142.91M |
| Stockholders' Equity | ($17.33M) | $23.97M | $166.95M | $227.81M | $135.60M | $105.34M |
| Retained Earnings | ($1.15B) | ($1.08B) | ($896.00M) | ($696.42M) | ($461.73M) | ($316.62M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($99.15M) | ($64.69M) | ($150.43M) | ($152.58M) | ($93.21M) | ($79.84M) |
| Investing Cash Flow | ($18.20M) | $73.18M | ($183.25M) | $20.79M | ($42.81M) | $18.10M |
| Financing Cash Flow | $2.97M | ($859.0K) | $274.80M | $137.04M | $135.64M | $168.63M |
| CapEx | $3.29M | $3.10M | $9.96M | $31.31M | $15.97M | $5.08M |
| Free Cash Flow | ($102.44M) | ($67.79M) | ($160.39M) | ($183.89M) | ($109.18M) | ($84.92M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 86.2% | 69.5% | - | - | - | - |
| Operating margin | -23.9% | -187.3% | -268.3% | - | - | - |
| EBITDA margin | -20.6% | -179.6% | -260.9% | - | - | - |
| Net margin | -38.5% | -220.2% | -285.6% | - | - | - |
| Free cash flow margin | -52.8% | -81.5% | -229.5% | - | - | - |
| FCF / Net income | 1.37 | 0.37 | 0.80 | 0.79 | 0.75 | 0.86 |
| R&D / Revenue | 39.1% | 89.0% | 130.7% | - | - | - |
| SG&A / Revenue | 71.0% | 165.0% | 198.0% | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -17.3% | -45.5% | -44.1% | -81.6% | -50.0% | -39.9% |
| Return on equity | 431.6% | -763.9% | -119.5% | -102.1% | -107.0% | -94.0% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.85 | 3.18 | 4.50 | 4.34 | 10.09 | 12.27 |
| Quick ratio | 2.52 | 2.92 | 4.25 | 4.14 | 10.09 | 12.27 |
| Cash ratio | 0.30 | 1.45 | 1.72 | 3.99 | 7.85 | 10.22 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -1.6x | -5.9x | -75.0x | - | - | -38.2x |
| Equity multiplier | -24.89 | 16.77 | 2.71 | 1.25 | 2.14 | 2.36 |
| Liabilities / Assets | 1.04 | 0.94 | 0.63 | 0.20 | 0.53 | 0.58 |
| Efficiency | ||||||
| Asset turnover | 0.45 | 0.21 | 0.15 | 0.00 | - | - |
| Inventory turnover | 0.66 | 0.94 | - | 0.00 | - | - |
| Days sales outstanding | 129d | 246d | 200d | - | - | - |
| Days inventory outstanding | 549d | 390d | - | - | - | - |
| Days payable outstanding | 113d | 127d | - | - | - | - |
| Cash conversion cycle | 566d | 509d | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 133.5% | 19.0% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | 189.4% | - | - | - | - | - |
| Operating income growth (YoY) | 70.2% | 17.0% | 10.6% | -44.0% | -50.4% | -29.0% |
| Net income growth (YoY) | 59.1% | 8.3% | 14.2% | -60.3% | -46.5% | -33.2% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -51.1% | 57.7% | 12.8% | -68.4% | -28.6% | -43.9% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | -85.6% | -26.7% | 68.0% | 28.7% | 461.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$194.13M totalProduct$112.13M · 57.8%
License$82.00M · 42.2%
Geographic
$80.00M totalEurope$80.00M · 100.0%
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
-1.78
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing AERIE PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.